Carotid Artery Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid artery surgery is the surgical management of disease affecting the carotid arteries — the principal paired arteries of the neck that supply oxygenated blood to the cerebral hemispheres, eyes, and face. Atherosclerotic narrowing at the carotid bifurcation (where the common carotid divides into internal and external branches in the mid-neck) is the dominant pathology, but carotid surgery also encompasses procedures for carotid body tumours (chemodectomas), fibromuscular dysplasia, carotid artery aneurysms, and traumatic carotid injuries. The primary clinical objective of carotid artery surgery is stroke prevention — either by removing the atherosclerotic plaque causing embolic TIAs and stroke (endarterectomy), or by restoring blood flow through a severely stenotic or occluded artery (bypass or interposition graft).

Carotid endarterectomy (CEA) is the most common carotid surgical procedure, involving opening the carotid bifurcation, physically removing the plaque under direct vision, and closing the artery with a patch. It is one of the best-evidenced surgical interventions in medicine, with benefit established by multiple Level I RCTs across thousands of patients over three decades. Carotid artery stenting (CAS) — a catheter-based alternative — deploys a metal stent across the plaque via a percutaneous femoral access route. For carotid body tumours and aneurysms, more complex open surgical techniques are required, sometimes involving vessel resection and graft interposition.

Vascular surgeons, neurovascular surgeons, and interventional radiologists share the management of carotid artery disease in a multidisciplinary context. Rapid access TIA clinics with same-day vascular imaging have dramatically shortened the time from symptom onset to treatment, reducing the risk of early recurrent disabling stroke.

Symptomatic atherosclerotic carotid stenosis — stenosis above 50% ipsilateral to a TIA or minor ischaemic stroke — is the primary indication for carotid surgery. The internal carotid artery disease causes stroke by two mechanisms: direct embolism of plaque fragments or thrombus to the middle cerebral artery territory, causing ischaemic stroke; and haemodynamic insufficiency from severe stenosis approaching total occlusion. Asymptomatic carotid stenosis above 60–70% is a secondary indication, particularly in patients with additional high-risk features such as contralateral occlusion, silent MRI brain infarcts, or rapidly progressive stenosis.

Carotid body tumours (paragangliomas) are highly vascular masses arising from chemoreceptor cells at the carotid bifurcation. Surgical resection — requiring meticulous dissection from the surrounding carotid vessels — is the treatment of choice, with pre-operative embolisation to reduce intraoperative blood loss and detailed anatomical planning on CT angiography. Carotid artery aneurysms — true aneurysms from atherosclerosis, connective tissue disorders, or post-dissection pseudoaneurysms — carry stroke risk from embolism and rupture risk, and require surgical repair with vessel reconstruction or bypass. Carotid artery dissection — a common cause of stroke in patients under 45 — is primarily managed medically with anticoagulation, but surgical repair is reserved for refractory cases.

Candidates for carotid endarterectomy must meet the clinical criteria of recently symptomatic stenosis above 50% with preserved functional status, fit surgical risk profile (perioperative risk below 6%), and adequate cerebral collateral reserve. Pre-operative assessment includes duplex ultrasound (primary imaging), CT angiography or MR angiography (anatomical planning), transthoracic echocardiography (cardiac risk stratification), and brain MRI (extent of existing ischaemic injury). Patients with significant coronary artery disease may require concomitant or staged coronary revascularisation before elective carotid surgery to minimise perioperative cardiac risk, though in symptomatic patients the urgency of carotid intervention may precede cardiac treatment.

Patients with carotid body tumours require preoperative CT angiography, MRI (bone involvement assessment), and often nuclear medicine imaging (DOPA-PET) for functional assessment and exclusion of bilateral or extra-adrenal paraganglioma. Pre-operative embolisation of the tumour feeding vessels reduces intraoperative blood loss but carries a small risk of stroke from embolisation of carotid territory vessels. For carotid aneurysms, surgical planning requires understanding of aneurysm extent (involvement of skull base vs. distal ICA), collateral flow (balloon test occlusion if carotid sacrifice is being considered), and access to vascular neurosurgery for high cervical lesions.

Standard carotid endarterectomy with patch angioplasty is the most evidence-supported technique. The choice of patch material — autologous saphenous vein, bovine pericardium, or PTFE — has been subject to randomised trials, with vein and bovine pericardial patches showing lowest restenosis rates. Eversion endarterectomy provides equivalent results and avoids patch material but requires more intraoperative experience to achieve adequate distal endpoint control. Both techniques can be performed under general or local (cervical block) anaesthesia, with local anaesthesia enabling awake neurological monitoring during clamping.

Carotid artery stenting (CAS) with distal embolic protection is the transcatheter alternative, performed under fluoroscopic guidance. Self-expanding nitinol stents (Acculink, Xact, Precise) are deployed across the plaque after pre-dilation with a small balloon. CAS is particularly suited to patients with surgical risk factors (prior surgery, radiation, high bifurcation). Carotid body tumour resection requires meticulous dissection of the tumour from the adventitia of the carotid arteries — using a subadventitial plane for Shamblin I–II tumours and requiring vessel resection and graft reconstruction for Shamblin III tumours with vessel encirclement. Carotid bypass grafting — using reversed great saphenous vein or PTFE — is required for carotid occlusion or large pseudoaneurysm where direct repair is not feasible. Carotid artery bypass using a saphenous vein or prosthetic (PTFE) conduit is required for carotid occlusion or large pseudoaneurysm where direct repair is not feasible. All patients receive dual antiplatelet therapy peri-operatively and lifelong single antiplatelet and statin therapy post-procedure to address the systemic atherosclerotic process.

Carotid endarterectomy has demonstrated unequivocal benefit in reducing stroke risk for symptomatic high-grade stenosis in three landmark trials (NASCET, ECST, VACSP). Five-year absolute risk reduction in ipsilateral stroke or perioperative death is approximately 17% for 70–99% stenosis in symptomatic patients, with the benefit concentrated in the first one to two years following surgery. Prompt surgery within two weeks of the index TIA prevents the highest-risk period for early recurrent disabling stroke, with number needed to treat as low as five to six patients in the highest-risk groups.

Carotid body tumour resection achieves cure in over 95% of Shamblin I–II tumours without sacrifice of the carotid arteries. For Shamblin III tumours requiring carotid resection and grafting, the combined procedure is technically demanding with higher cranial nerve injury rates, but cure rates remain excellent when R0 resection is achieved. Carotid aneurysm repair restores normal vessel patency, eliminates the embolic source, and prevents rupture — with outcomes dependent on aneurysm location, size, and the reconstruction technique.

Perioperative stroke remains the primary risk of carotid endarterectomy, occurring in 1.5–3% at experienced centres. The mechanism is embolic in approximately 70% (plaque fragments, thrombus) and haemodynamic (hypoperfusion during clamping) in 30%. Death within 30 days occurs in 0.5–1.5%. Cranial nerve injury affects 5–10% of patients; most are temporary but permanent injury occurs in below 1%. Wound haematoma requiring evacuation affects 2–5% of patients. For carotid body tumour surgery, cranial nerve injury rates are substantially higher — particularly the vagus, hypoglossal, and sympathetic chain (causing Horner syndrome) — and increase with tumour size and Shamblin class. Carotid artery stenting carries a higher peri-procedural stroke rate than CEA in older patients due to aortic arch emboli during catheter manipulation but lower rates of myocardial infarction and cranial nerve injury.

After carotid endarterectomy, patients are monitored in a high-dependency area for 12–24 hours with neurological observations every 30 minutes, blood pressure management (target 120–150 systolic), and neck haematoma vigilance. Patients are discharged on day one to two with antiplatelet therapy, high-intensity statin, and antihypertensives. Duplex ultrasound surveillance at one month, six months, and annually monitors patency and restenosis. After carotid body tumour surgery, patients require long-term neurovascular assessment for cranial nerve recovery and post-operative imaging (CT or MRI) at six months to confirm complete resection. For carotid aneurysm repair, duplex or CT angiographic surveillance at six months and then annually confirms graft patency and freedom from recurrence.

Carotid endarterectomy costs USD 20,000–50,000 in the United States; GBP 8,000–18,000 privately in the UK. In India (Apollo, Fortis, Narayana), CEA is performed for USD 3,000–7,000 total. Carotid body tumour resection — a complex vascular procedure — costs USD 30,000–80,000 in the US versus USD 6,000–15,000 in India. Carotid artery stenting is similar to CEA in pricing at most centres. Thailand (Bumrungrad) charges USD 8,000–15,000 for CEA; Turkey (Acibadem) USD 5,000–12,000. Patients seeking carotid surgery abroad should confirm the vascular surgery team performs high-volume CEA with outcomes data, has ICU support, and provides neurovascular post-operative monitoring. India leads in cost-effectiveness with carotid endarterectomy costing USD 3,000–7,000 at accredited centres such as Apollo, Fortis, and Medanta, compared to USD 15,000–40,000 in the US. Thailand and Turkey offer comparable quality at USD 5,000–12,000. International patients should confirm surgeon carotid surgery volume (minimum 50 cases/year), hospital stroke unit capability, and neuromonitoring availability.

Optimal medical therapy is the primary alternative for low-grade stenosis, asymptomatic stenosis below 60%, and patients unfit for surgery — comprising statins, antiplatelets, blood pressure control below 130/80 mmHg, and smoking cessation. Carotid artery stenting is the procedural alternative to CEA for anatomically or medically high-surgical-risk patients. For carotid body tumours, stereotactic radiosurgery (Gamma Knife, CyberKnife) is an option for inoperable tumours or patients declining surgery, providing local control in 80–90% of cases but not achieving the histological cure of surgery. Endovascular carotid aneurysm treatment using covered stents or coil embolisation is increasingly reported for distal high cervical or intracranial carotid aneurysms not amenable to open surgical repair.